Tuberculosis is the leading cause of death from a single infectious agent worldwide; therefore, the need for new antitubercular drugs is desperate. The recently validated target salicylate synthase MbtI is the first enzyme involved in the biosynthesis of mycobactins, compounds able to chelate iron, an essential cofactor for the survival of Mycobacterium tuberculosis in the host. Here, we report on the synthesis and biological evaluation of chromane-based compounds as new potential inhibitors of MbtI. Our approach successfully allowed the identification of a novel lead compound (1), endowed with a promising activity against this enzyme (IC50= 55 µM). Molecular modeling studies were performed in order to evaluate the binding mode of 1 and rationalize the preliminary structure-activity relationships, thus providing crucial information to carry out further optimization studies.

New chromane-based derivatives as inhibitors of mycobacterium tuberculosis salicylate synthase (mbti): Preliminary biological evaluation and molecular modeling studies / Pini, Elena; Poli, Giulio; Tuccinardi, Tiziano; Chiarelli, Laurent Roberto; Mori, Matteo; Gelain, Arianna; Costantino, Luca; Villa, Stefania; Meneghetti, Fiorella; Barlocco, Daniela. - In: MOLECULES. - ISSN 1420-3049. - 23:7(2018), pp. 1-14. [10.3390/molecules23071506]

New chromane-based derivatives as inhibitors of mycobacterium tuberculosis salicylate synthase (mbti): Preliminary biological evaluation and molecular modeling studies

Costantino, Luca;
2018

Abstract

Tuberculosis is the leading cause of death from a single infectious agent worldwide; therefore, the need for new antitubercular drugs is desperate. The recently validated target salicylate synthase MbtI is the first enzyme involved in the biosynthesis of mycobactins, compounds able to chelate iron, an essential cofactor for the survival of Mycobacterium tuberculosis in the host. Here, we report on the synthesis and biological evaluation of chromane-based compounds as new potential inhibitors of MbtI. Our approach successfully allowed the identification of a novel lead compound (1), endowed with a promising activity against this enzyme (IC50= 55 µM). Molecular modeling studies were performed in order to evaluate the binding mode of 1 and rationalize the preliminary structure-activity relationships, thus providing crucial information to carry out further optimization studies.
2018
23
7
1
14
New chromane-based derivatives as inhibitors of mycobacterium tuberculosis salicylate synthase (mbti): Preliminary biological evaluation and molecular modeling studies / Pini, Elena; Poli, Giulio; Tuccinardi, Tiziano; Chiarelli, Laurent Roberto; Mori, Matteo; Gelain, Arianna; Costantino, Luca; Villa, Stefania; Meneghetti, Fiorella; Barlocco, Daniela. - In: MOLECULES. - ISSN 1420-3049. - 23:7(2018), pp. 1-14. [10.3390/molecules23071506]
Pini, Elena; Poli, Giulio; Tuccinardi, Tiziano; Chiarelli, Laurent Roberto; Mori, Matteo; Gelain, Arianna; Costantino, Luca; Villa, Stefania; Meneghetti, Fiorella; Barlocco, Daniela
File in questo prodotto:
File Dimensione Formato  
molecules-23-01506.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 3.5 MB
Formato Adobe PDF
3.5 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1166113
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 28
social impact